Physician profile
Robert D Slinker
NPI 1619016383
$3,618.06
in general payments reported to CMS, 2019-2025
25 companies · $955 in 2025
The $955 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $301 · 2021: $373 · 2022: $291 · 2023: $603 · 2024: $623 · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,163 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,162.50 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $513.09 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Bausch & Lomb Americas INC. | $509.60 | 2023-2025 | Miebo, Vyzulta, Infuse |
| Allergan, INC. | $494.23 | 2019-2022 | |
| Harrow Eye, LLC | $299.20 | 2024-2025 | Vevye |
| Johnson & Johnson Surgical Vision, INC. | $270.06 | 2020-2023 | Star S4 Ir |
| Novartis Pharmaceuticals Corporation | $201.58 | 2020-2023 | |
| Sun Pharmaceutical Industries INC. | $197.14 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $189.02 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $163.67 | 2024-2025 | Acthar |
| Genmab U.S., INC. | $124.84 | 2022 | |
| Shire North American Group INC | $94.95 | 2019 | |
| Alcon Vision LLC | $82.91 | 2019-2024 | Precision 1, Eysuvis |
| Coopervision INC. | $80.68 | 2019-2025 | Myday Contact Lens, Biofinity Contact Lens |
| Eyevance Pharmaceuticals LLC | $76.30 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $46.57 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $44.66 | 2024-2025 | Izervay |
| Johnson & Johnson Vision Care, INC. | $41.35 | 2019-2024 | |
| Glaukos Corporation | $32.32 | 2024 | Idose |
| Lumenis, INC | $31.03 | 2021 | |
| Quidel Corporation | $26.59 | 2019 | |
| Sight Sciences, INC. | $24.60 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.12 | 2020 | |
| Abb Con-Cise Optical Group LLC | $22.75 | 2024 | Spectacle Lenses, Contact Lens |
| Maculogix, INC. | $16.03 | 2019 | |
| Oyster Point Pharma, INC. | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Slinker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.